The high incidence of LOH and EMAST in PMBCL is not associated with standard therapy failure but its role in tumor sensitivity to immunotherapy is still unclear and needs future investigation in combination with the tumor mutational burden and PD-1/PDL-1 level evaluation. This evidence concerns the gene CD274 and neoplasm.